EditCo Bio, Inc.

The partnership is set to enhance EditCo’s engineered cell solution offerings, allowing researchers to create gene-edited models. Credit: vchal / Shutterstock. EditCo Bio has entered a strategic licensing agreement with Promega, securing access to the latter’s protein-tagging and bioluminescent identification technologies. Promega’s HiBiT, HaloTag, and NanoLuc technologies will be integrated into EditCo’s clustered regularly interspaced short palindromic repeats (CRISPR) knock-in services. This partnership is set to enhance EditCo’s engineered cell solution offerings, allowing researchers to create gene-edited models with reproducibility and reliability, which are crucial for a variety of applications. EditCo noted that the agreement facilitates the company to offer not only genomic knock-ins but also functional validation services. Its CRISPR knock-ins claim to alter cells into biosensors, which are ideal for protein quantification, the discovery of drugs, and cell-based assays. This ensures that the engineered cells uphold protein expression, activity, and stability. Such capabilities are vital for researchers needing cell models optimised for quantitative protein analysis. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence HiBiT is a bioluminescent peptide tag for protein expression analysis and live cell interaction. The protein labelling system HaloTag enables covalent bonding of fluorescent and bioluminescent probes for protein interaction studies, and NanoLuc is a luciferase enzyme for real-time monitoring of molecular and cellular processes. EditCo stated that the agreement is set to support the custom-engineered cell line development using these technologies strictly for research purposes. Researchers can now utilise these tools to streamline their experimental workflows. EditCo Bio’s chief scientific officer Travis Maures said: “Our collaboration with Promega underscores EditCo’s commitment to delivering industry-leading CRISPR-engineered cells that go beyond genetic modification by incorporating functional validation. “By integrating HiBiT, HaloTag, and NanoLuc into our knock-in workflows, we provide researchers with powerful tools to track protein expression, interactions, and activity with high sensitivity and accuracy. This partnership will accelerate discoveries in functional genomics, drug development, and therapeutic research.”

Leadership change simultaneous to the Eclipse Cell Engineering platform spinout as EditCo Bio REDWOOD CITY, Calif., March 27, 2024 /PRNewswire/ -- Synthego Corporation, a leading provider of genome engineering solutions, announced that Paul Dabrowski will step down as Chief Executive Officer, effective immediately. Craig Christianson has been appointed Chief Executive Officer following an extensive search process. Mr. Dabrowski, a co-founder of the company, will continue his role as a Board Director and advisor. Additionally, the company announces the divestiture of the Eclipse Cell Engineering platform as EditCo Bio, Inc., enabling Synthego's unique focus on therapeutic applications of CRISPR. "Founding and growing Synthego the past 12 years has been the privilege of a lifetime," said Dabrowski. "Our team has transformed the CRISPR landscape by staying true to our values and providing everyone, from individual scientists to the world's leading biotechnology companies, with unprecedented access to advanced genome engineering. I'm confident Craig is an ideal fit to further our mission by building a robust commercial engine leveraging Synthego's platform - in addition to his impeccable track record, he embodies Synthego's culture of innovation and excellence. As the world enters the era of CRISPR based therapeutics, Synthego is now focused to be the premier supplier to hundreds of programs entering the clinic." Christianson has a track record of spearheading global commercial strategies, business development and operations to build global life sciences and other businesses. He joins Synthego from Water Street Healthcare Partners, preceded by 12 years with global biotechnology company Promega Corporation where he led commercial operations, accelerating their growth to $700M+ in annual sales through profit-driven strategies and successful digital transformation. "I am honored to join this pioneering organization which plays an important role in the impact CRISPR has on life science research and clinical development," said Christianson. "Paul is a visionary who has built a foundation upon which Synthego will become the best partner for clients in terms of co-development and regulatory compliance for the advancement of therapies and, ultimately, human health." Christianson's appointment, along with the spinout of EditCo Bio, previously operating as Synthego's Eclipse platform, reinforces Synthego's commitment to provide CRISPR therapeutic developers with best-in-class guide RNAs. With its state-of-the-art GMP facility and extensive experience of producing leading products, Synthego is uniquely positioned to address escalating clinical requirements and changing regulatory frameworks. Bolstered by the FDA approval of the first CRISPR-based therapy, Synthego is more dedicated than ever to accelerating life-saving technologies for improved human health in its next chapter. For more information, click here. About Synthego: Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. Based on a foundation of engineering and chemistry, Synthego leverages automation and machine learning to synthesize high-quality CRISPR reagents for science at scale. Synthego's mission is to enable agile life science research and development from discovery through clinical trials by providing scientists with comprehensive CRISPR solutions for each phase coupled with full technical and regulatory support from industry-leading experts. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation, enabling the next generation of medicines by delivering genome editing at an unprecedented scale. SOURCE Synthego

EditCo is focused on the development and manufacture of highly optimized CRISPR guide RNA designs and edited cells for the global cell biology and gene therapy research markets REDWOOD CITY, Calif., March 27, 2024 /PRNewswire/ -- EditCo Bio, Inc. announced that it has launched its business with the acquisition of Synthego's engineered cell solutions and enhanced guide RNA business. Borne from Synthego's cell engineering expertise, EditCo is uniquely positioned to deliver edited cells and highly optimized guide RNA designs for the rapidly expanding CRISPR market. EditCo will operate as an independent business with financing and support from life sciences investment firm Telegraph Hill Partners. Continue Reading EditCo Bio Company EditCo will offer researchers simple one-click access to high-quality engineered cells with guaranteed edits in their desired targets, minimizing time and effort spent in experiments. By ushering in unprecedented predictability in biology, EditCo lays the foundation for rapid outcomes in basic biology and cell and gene therapy research. As an independent entity, EditCo will have the flexibility to invest in and scale up its capabilities to best meet the needs of its global customers. The company plans to launch new products and services, expand commercial operations and continue to build on its leadership position in cell engineering. EditCo will be led by former Synthego President and Chief Operating Officer, John Tan, who has been appointed Chief Executive Officer. Travis Maures, PhD, former Chief Technology Officer of Synthego will be Chief Scientific Officer of EditCo. "EditCo begins its journey with the benefit of significant investment in our cell engineering capabilities while part of Synthego," said John Tan. "Our proven products and manufacturing operations enable us to immediately serve customers with industry-leading CRISPR solutions and world-class customer support." "CRISPR continues to demonstrate its power to accelerate progress across the drug discovery pipeline and will ultimately lead to more and better validated drugs entering the clinic," said Travis Maures. "EditCo's products and manufacturing operations have already been proven within Synthego, enabling us to immediately initiate commercial operations and deliver validated, customer-focused solutions that provide industry-leading gene editing efficacy and reproducibility." As an independent company, EditCo will establish unique partnerships, invest in new product innovation, and pursue strategic investment opportunities. To support its operations and growth initiatives, EditCo has closed a financing from Telegraph Hill Partners. This funding strengthens the company's ability to create long-term value and align with the unique customer needs across both basic research and preclinical phases of CRISPR-based therapy development. EditCo is based in Redwood City, California and can be found online at . About EditCo Bio, Inc. EditCo Bio is a pioneer in the development of cells as reagents. The company began as the gene editing business at Synthego and, through that experience, has gained a deeper understanding of the critical role that high-quality, easily accessible reagents play in advancing scientific discoveries. EditCo is bringing the same ease of ordering, reliability, and rapid delivery to the biology of engineered cells. This new direction promises to transform how engineered cells are accessed and utilized in research, making them as efficacious and as reproducible as traditional reagents. About Telegraph Hill Partners Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in life science, medical technology, and healthcare companies. For more information, please see . SOURCE Synthego